Unlocking the Untapped Power of Thyroid Signals for Rapid Hair Regrowth
On February 5, 2024, researchers announced the successful completion of a Phase 2a clinical trial evaluating a novel, first-in-class topical solution called TDM-105795. This represents a major scientific breakthrough because it introduces a completely new biological tool to the hair loss space: thyromimetics. By mimicking thyroid hormones locally on the scalp, the treatment successfully wakes up dormant hair-growing cells and achieves a highly significant increase in thick, visible hair count without triggering any of the hormonal imbalances associated with standard thyroid therapies.
What Is It and How Does It Work?
TDM-105795 is a small-molecule topical solution developed by Technoderma Medicines. It is designed to act as a highly targeted, potent thyromimetic—a compound that mimics the positive effects of thyroid hormones.
Historically, scientists have known that thyroid hormones are crucial regulators of the hair cycle. However, taking thyroid hormones orally or using general creams is extremely dangerous, as it can disrupt your body’s endocrine system and cause severe heart, thyroid, or metabolic complications.
This treatment solves that problem through localized Thyroid Receptor Activation:
-
Direct Binding: When applied to the scalp once daily, the molecule penetrates the skin and binds specifically to the target thyroid hormone receptor proteins inside your hair follicle cells.
-
Activating Dormant Stem Cells: This binding sends a direct signal to dormant hair follicle stem cells, forcing them to activate and divide.
-
The Growth Phase (Anagen) Jumpstart: The treatment acts like a metabolic battery, pushing resting (telogen) hair follicles rapidly back into their active growth (anagen) phase.
-
No Bloodstream Escape: Because the molecule is engineered with poor systemic absorption and a very short survival window in the bloodstream (short elimination half-life), it does its work directly on the scalp and is quickly metabolized if it attempts to travel elsewhere, avoiding body-wide side effects.
The Science: Significant Hair Gains in a 16-Week Human Trial
The Phase 2a double-blind, randomized, placebo-controlled study followed 71 male participants with mild to moderate pattern baldness (Norwood Scale 3v, 4, or 5) across 13 clinical sites in the United States. Over 16 weeks of daily application, scientists measured the change in the number of thick, non-baby hairs (Target Area Hair Count) in a 1 cm² test area:
-
High Strength (0.02% formulation): Achieved an average increase of 24.3 hairs/cm².
-
Low Strength (0.0025% formulation): Achieved an average increase of 20.3 hairs/cm².
-
Placebo Solution: Achieved an average increase of only 14.0 hairs/cm².
-
Safety Profile: Both concentrations were highly tolerated with no material safety issues. Blood tests confirmed that there was extremely low to zero systemic exposure, meaning the thyroid levels throughout the rest of the body remained perfectly normal.
“We are excited to see that TDM-105795 in the current Phase 2 testing has demonstrated hair growth in Androgenetic Alopecia with a very favorable safety profile. We look forward to moving the clinical program forward to better assess how longer-term treatment is able to provide global improvement in hair coverage.” — Dr. Arthur P. Bertolino, Chief Medical Officer at Technoderma Medicines.
Read next
Whats the best shampoo for hair loss?
When Will It Be Available?
-
Current Stage: Following these successful Phase 2a proof-of-concept results, the clinical development program is being prepared for larger, late-stage trials to refine the ideal dosing and confirm long-term safety.
-
Timeline: If future trials replicate this success, the drug is projected to submit its final registration data to health authorities, with commercial availability expected around 2028 or 2029.
How you can benefit from this treatment now
Because TDM-105795 is an investigational drug, it cannot yet be purchased or prescribed at standard pharmacies.
-
Do Not Attempt DIY Thyroid Scalp Treatments: Experts strongly warn against applying crushed thyroid pills or standard hormone creams to the scalp. Doing so can lead to dangerous systemic absorption, causing severe cardiovascular complications, anxiety, chronic fatigue, and even thyroid-induced hair shedding.
-
Monitor Future Phase 2b/3 Trials: If you are a male with pattern baldness, you can track the clinical development of TDM-105795 via ClinicalTrials.gov using the identifier NCT05802173. This is the safest way to find out if clinical sites in your area are enrolling volunteers for upcoming, late-stage trials of this thyromimetic treatment.
-
Support Follicle Metabolism Naturally: While waiting for thyromimetic drugs to reach the pharmacy, you can discuss safe, existing methods to boost follicle cell metabolism with a dermatologist. Approaches like Low-Level Laser Therapy (LLLT) or consistent microneedling help stimulate blood flow and support the scalp’s local growth signals, keeping follicles receptive to advanced cellular treatments.
Sources:
